NCT03918239View on ClinicalTrials.gov

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

November 13, 2019

Study Completion Date

November 13, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

SHP643

Participants will receive injection of SHP643.

Trial Locations (1)

33014

Clinical Pharmacology of Miami, LLC, Miami

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT03918239 - A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants. | Biotech Hunter | Biotech Hunter